Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases

Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases is a phase 2, interventional study registered as NCT07570914 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 28 participants, started 2026-05-30 and due to reach its primary completion in 2027-05-30. Interventions recorded: Liposomal Irinotecan; Oxaliplatin; Capecitabine; hepatic arterial infusion chemotherapy (HAIC). Conditions listed: Colorectal Cancer Liver Metastases (CRLM); Colorectal Cancer; Liver Metastasis. Primary outcome: 3-Year Disease-Free Survival Rate. Colorectal eligibility wording from the registry: "Completion of radical resection of the colorectal primary tumor and liver metastases within 12 weeks before enrollment, with postoperative imaging showing no residual lesion, recurrence, or extrahepatic metastasis, indicating no evidence of disease". No results are recorded here; the registry entry is the source.